OGT forms Scientific Advisory Board
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, announced today the formation of a Scientific Advisory Board chaired by Peter Rigby, Emeritus Professor of Developmental Biology at the Institute of Cancer Research and Deputy Chairman of the Board of Governors at the Wellcome Trust.
Professor Peter W J Rigby PhD, FRS, FMedSci has been on the Wellcome Trust’s Board of Governors since 2008 and was appointed Deputy Chairman in 2010. He also serves as a member of the Council of Marie Curie Cancer Care, he is a Fellow of the Royal Society and of the Academy of Medical Sciences, and a Member of the European Molecular Biology Organisation. From 1999 to 2011, he was Chief Executive of the Institute of Cancer Research (ICR), where he remains as Professor of Developmental Biology.
Joining Professor Rigby on OGT’s Scientific Advisory Board are Professors Jorge Reis-Filho, Martin Bobrow and Chris Holmes.
Professor Jorge Reis-Filho PhD, FRCPath, is Professor of Molecular Pathology at the Institute of Cancer Research and has made major contributions to the molecular characterisation of breast cancer subtypes. Professor Reis-Filho will shortly take up the position of Member and Attending Pathologist at the Department of Pathology, and Affiliate Member of the Human Oncology and Pathogenesis Programme at the Memorial Sloan-Kettering Cancer Center.
Professor Martin Bobrow PhD, FRS, FMedSci, was head of Medical Genetics at Guy’s Hospital and then the University of Cambridge, and Deputy Chairman of the Wellcome Trust and of the Nuffield Council on Bioethics.
Professor Chris Holmes PhD, is Professor of Biostatistics at the University of Oxford, Head of Statistical Genetics at the Wellcome Trust Centre for Human Genetics, and an elected Member of Council of the Royal Statistical Society (RSS).
Professor Sir Ed Southern, Chairman of OGT, said: “Over recent years, OGT has grown significantly and the breadth of our science has increased considerably extending into cytogenetics, cancer and the biomarker fields. We believe that it is vital for the company’s future scientific and commercial development to appoint an experienced team of senior scientific advisors, all specialists in the field of cancer research and genetics, to our SAB. We are delighted that such a prestigious group of individuals in Peter, Jorge, Martin and Chris have agreed to come on board.”
Professor Peter W J Rigby, Chairman of OGT’s SAB, added: “OGT is at the forefront of cytogenetics and biomarker discovery and is driving the detection and diagnosis of cancers at the molecular level. Advancing research into cancer and finding new therapies to treat patients has dominated our own careers and we are therefore pleased to apply our experience to help guide OGT in its future scientific and corporate progression.”
For more information, please contact:
Oxford Gene Technology
Stephen Archibald, Marketing Communications Manager
College Hill (PR Agency for OGT)
Melanie Toyne Sewell / Jen Lewis
College Hill, The Registry, Royal Mint Court, London, EC3N 4QN
T: +44 (0) 20 7457 2029
Notes for editors:
A photograph of Peter Rigby is available on request from College Hill.
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.